Oncology and Hematology - Global Oncology Academy

401-416 of 789

Differentiating Large Cell Neuroendocrine Carcinoma from Other Lung Cancers
Differentiating Large Cell Neuroendocrine Carcinoma from Other Lung Cancers
Project Oncology®
Differentiating Large Cell Neuroendocrine Carcinoma from Other Lung Cancers
Balazs Halmos, MD, MS
- Balazs Halmos, MD, MS
Personalized Treatment Pathways in Endometrial Cancer: A Molecular Approach
Personalized Treatment Pathways in Endometrial Cancer: A Molecular Approach
Project Oncology®
Personalized Treatment Pathways in Endometrial Cancer: A Molecular Approach
Kathleen N. Moore, MD
- Kathleen N. Moore, MD
Navigating Fertility Preservation in Young Patients With Endometrial Cancer
Navigating Fertility Preservation in Young Patients With Endometrial Cancer
Project Oncology®
Navigating Fertility Preservation in Young Patients With Endometrial Cancer
Kathleen N. Moore, MD
- Kathleen N. Moore, MD
Rewriting the Prognosis: Advances in Endometrial Cancer Diagnosis and Treatment
Rewriting the Prognosis: Advances in Endometrial Cancer Diagnosis and Treatment
Project Oncology®
Rewriting the Prognosis: Advances in Endometrial Cancer Diagnosis and Treatment
Kathleen N. Moore, MD
- Kathleen N. Moore, MD
Subcutaneous Isatuximab Matches IV in Multiple Myeloma: Insights from IRAKLIA
Subcutaneous Isatuximab Matches IV in Multiple Myeloma: Insights from IRAKLIA
Project Oncology®
Subcutaneous Isatuximab Matches IV in Multiple Myeloma: Insights from IRAKLIA
Marlene Mimi Maeusli, PhD.
- Marlene Mimi Maeusli, PhD.
Patient Perspectives on Subcutaneous vs IV Immunotherapies in Oncology Care
Patient Perspectives on Subcutaneous vs IV Immunotherapies in Oncology Care
Project Oncology®
Patient Perspectives on Subcutaneous vs IV Immunotherapies in Oncology Care
Ryan Quigley
- Ryan Quigley
From Infusion to Injection: Can Subcutaneous Delivery Match Intravenous Standards in Oncology?
From Infusion to Injection: Can Subcutaneous Delivery Match Intravenous Standards in Oncology?
Project Oncology®
From Infusion to Injection: Can Subcutaneous Delivery Match Intravenous Standards in Oncology?
Are Subcutaneous Immunotherapies Expanding Access and Efficiency in Cancer Care?
Are Subcutaneous Immunotherapies Expanding Access and Efficiency in Cancer Care?
Project Oncology®
Are Subcutaneous Immunotherapies Expanding Access and Efficiency in Cancer Care?
Ryan Quigley
- Ryan Quigley
Subcutaneous Pembrolizumab in mNSCLC: A Potential Shift in the Delivery Landscape
Subcutaneous Pembrolizumab in mNSCLC: A Potential Shift in the Delivery Landscape
Project Oncology®
Subcutaneous Pembrolizumab in mNSCLC: A Potential Shift in the Delivery Landscape
Redefining First-Line Treatment in Endometrial Cancer: The Role of Immunotherapy
Redefining First-Line Treatment in Endometrial Cancer: The Role of Immunotherapy
Project Oncology®
Redefining First-Line Treatment in Endometrial Cancer: The Role of Immunotherapy
Brian Slomovitz, MD
- Brian Slomovitz, MD
From Infusion Chair to Clinic Visit: How Subcutaneous Nivolumab May Simplify RCC Care
From Infusion Chair to Clinic Visit: How Subcutaneous Nivolumab May Simplify RCC Care
Project Oncology®
From Infusion Chair to Clinic Visit: How Subcutaneous Nivolumab May Simplify RCC Care
Advancing Endometrial Cancer Care: ADCs and Biomarker-Based Therapies
Advancing Endometrial Cancer Care: ADCs and Biomarker-Based Therapies
Project Oncology®
Advancing Endometrial Cancer Care: ADCs and Biomarker-Based Therapies
Brian Slomovitz, MD
- Brian Slomovitz, MD
Putting Patients First: Personalized Care in Metastatic Breast Cancer
Putting Patients First: Personalized Care in Metastatic Breast Cancer
On the Frontlines of Metastatic Breast Cancer
Putting Patients First: Personalized Care in Metastatic Breast Cancer
Ashley Baker, MSN, PMHNP; Giancarlo Moscol, M.D.
- Ashley Baker, MSN, PMHNP
- Giancarlo Moscol, M.D.
Insights From Global Key Opinion Leaders on Regional Regulatory and Guideline Nuances to Optimize Melanoma Management
Insights From Global Key Opinion Leaders on Regional Regulatory and Guideline Nuances to Optimize Melanoma Management
MinuteCE®
Insights From Global Key Opinion Leaders on Regional Regulatory and Guideline Nuances to Optimize Melanoma Management
Hussein Tawbi, MD, PhD; Paolo A. Ascierto, MD
1.00 program credit
- Hussein Tawbi, MD, PhD
- Paolo A. Ascierto, MD
1.00 program credit
Clinical Decision-Making in Metastatic Breast Cancer: Optimizing Sequencing Choices
Clinical Decision-Making in Metastatic Breast Cancer: Optimizing Sequencing Choices
On the Frontlines of Metastatic Breast Cancer
Clinical Decision-Making in Metastatic Breast Cancer: Optimizing Sequencing Choices
Ashley Baker, MSN, PMHNP; Giancarlo Moscol, M.D.
- Ashley Baker, MSN, PMHNP
- Giancarlo Moscol, M.D.
Clinical Data Prompting Guideline Updates for Subcutaneous ICIs in Melanoma
Clinical Data Prompting Guideline Updates for Subcutaneous ICIs in Melanoma
MinuteCE®
Clinical Data Prompting Guideline Updates for Subcutaneous ICIs in Melanoma
Hussein Tawbi, MD, PhD; Sapna Patel, MD
1.00 program credit
- Hussein Tawbi, MD, PhD
- Sapna Patel, MD
1.00 program credit

26/11